2-(1-苄基-4-哌啶基)-2-氰基乙酸乙酯 | 1463-52-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2-(1-苄基-4-哌啶基)-2-氰基乙酸乙酯
• 英文名称: ethyl 2-(1-benzylpiperidin-4-ylidene)-2-cyanoacetate
• 英文别名: ethyl 2-cyano-2-[1-(phenylmethyl)-4-piperidinylidene]acetate
• CAS: 1463-52-1
• 化学式: C₁₇H₂₀N₂O₂
• 分子量: 284.358
• InChiKey: HSTSIRUENGPGSB-UHFFFAOYSA-N

物化性质

• 熔点：
  64-67°C
• 沸点：
  430.4±35.0 °C(Predicted)
• 密度：
  1.148±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  53.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  2-(1-苄基-4-哌啶基)-2-氰基乙酸乙酯 在 盐酸 、 sodium hydroxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以86%的产率得到2-(1-苄基-4-哌啶)乙腈
  参考文献：
  名称：

  Novel coumarin-3-carboxamides bearing N-benzylpiperidine moiety as potent acetylcholinesterase inhibitors

  摘要：

  Some novel coumarin-3-carboxamide derivatives linked to N-benzylpiperidine scaffold were synthesized and evaluated as acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitors. The screening results showed that most of compounds exhibited potent anti-AChE activity in the range of nM concentrations. Among them, compound 10c bearing an N-ethylcarboxamide linker and a 6-nitro substituent showed the most potent activity (IC50 = 0.3 nM) and the highest selectivity (SI = 26,300). Compound 10c was 46-fold more potent than standard drug donepezil against AChE. The kinetic study revealed that compound 10c exhibited mixed-type inhibition against AChE. Protein-ligand docking study demonstrated that the target compounds have dual binding site interaction mode and these results are in agreement with kinetic study. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.10.024
• 作为产物：
  描述：

  N-苄基哌啶酮 在 盐酸 、 sodium tetrahydroborate 作用下， 以 二氯甲烷 为溶剂， 生成 2-(1-苄基-4-哌啶基)-2-氰基乙酸乙酯
  参考文献：
  名称：

  Novel coumarin-3-carboxamides bearing N-benzylpiperidine moiety as potent acetylcholinesterase inhibitors

  摘要：

  Some novel coumarin-3-carboxamide derivatives linked to N-benzylpiperidine scaffold were synthesized and evaluated as acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitors. The screening results showed that most of compounds exhibited potent anti-AChE activity in the range of nM concentrations. Among them, compound 10c bearing an N-ethylcarboxamide linker and a 6-nitro substituent showed the most potent activity (IC50 = 0.3 nM) and the highest selectivity (SI = 26,300). Compound 10c was 46-fold more potent than standard drug donepezil against AChE. The kinetic study revealed that compound 10c exhibited mixed-type inhibition against AChE. Protein-ligand docking study demonstrated that the target compounds have dual binding site interaction mode and these results are in agreement with kinetic study. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.10.024

文献信息

• [EN] INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL<br/>[FR] INHIBITEURS DU CANAL POTASSIQUE MÉDULLAIRE EXTERNE RÉNAL
  申请人：MERCK SHARP & DOHME

  公开号：WO2015100147A1

  公开（公告）日：2015-07-02

  Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included.

  公开了公式I的新型螺环化合物及其药学上可接受的盐，作为ROMK（Kir1.1）通道的抑制剂。这些化合物可用作利尿剂和/或钠利尿剂，并用于治疗和预防包括高血压、心力衰竭和慢性肾脏疾病在内的心血管疾病以及与过多盐分和水分潴留有关的疾病。还包括药物组合物和治疗方法。
• [EN] INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL<br/>[FR] INHIBITEURS DU CANAL POTASSIQUE MÉDULLAIRE EXTERNE RÉNAL
  申请人：MERCK SHARP & DOHME

  公开号：WO2015096035A1

  公开（公告）日：2015-07-02

  Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included.

  公开了公式I的新颖螺环化合物及其药学上可接受的盐，作为ROMK（Kir1.1）通道的抑制剂。这些化合物可用作利尿剂和/或钠利尿剂，并用于治疗和预防包括高血压、心力衰竭和慢性肾病在内的心血管疾病以及与过多盐分和水分潴留有关的疾病。还包括药物组合物和治疗方法。
• Chemoselective Reduction of α-Cyano Carbonyl Compounds: Application to the Preparation of Heterocycles
  作者：Scott R. Pollack、Jeffrey T. Kuethe

  DOI：10.1021/acs.orglett.6b03285

  日期：2016.12.16

  in synthesis. General methods for their preparation typically afford α and β disubstitution patterns or β only. Molecules with only α-substituents (β-hydrogen) are much less well-known. A chemoselective reductive tautomerization of α-cyanoacetates, using DIBAL-H, has been developed to access these valuable synthons. α,β-Unsaturated cyanoacetates and α-cyanoketones can, also, be selectively reduced via

  β-氨基丙烯酸酯是反应性中间体，是合成中有用的组成部分。制备它们的通用方法通常仅提供α和β破坏模式或仅提供β。仅具有α-取代基（β-氢）的分子是众所周知的。已经开发出使用DIBAL-H进行α-氰基乙酸酯化学选择性还原互变异构的方法，以获取这些有价值的合成子。也可以通过该方法选择性地还原α，β-不饱和氰基乙酸酯和α-氰基酮。使用这些β-烯氨基羰基化合物制备了一系列杂环。
• [EN] 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF<br/>[FR] 2-CYANOPYRROLOPYRIMIDINES ET UTILISATIONS PHARMACEUTIQUES DE CELLES-CI
  申请人：NOVARTIS AG

  公开号：WO2004069256A1

  公开（公告）日：2004-08-19

  The invention relates to pyrrolo pyrimidines of formula (I), wherein Y represents -(CH2)t-O- or -(CH2)r-S-, p is 1 or 2, r is 1, 2 or 3, t is 1, 2 or 3, or Y is -(CH2)j- or -CH=CH-, j is 1 or 2; p is 1 or 2, or Y is -(CH2)f-, f is 1 or 2, p is 1, and the further radicals and symbols have the meaning as defined herein; their preparation, their use as pharmaceuticals, pharmaceutical compositions containing them, the use of such a compound for the manufacture of a pharmaceutical preparation for the treatment of neuropathic pain and to a method for the treatment of such a disease in animals, especially in humans.

  该发明涉及公式（I）中的吡咯嘧啶，其中Y代表-(CH2)t-O-或-(CH2)r-S-，p为1或2，r为1、2或3，t为1、2或3，或Y为-(CH2)j-或-CH=CH-，j为1或2；p为1或2，或Y为-(CH2)f-，f为1或2，p为1，以及进一步的基团和符号具有如本文所定义的含义；它们的制备，它们作为药物的用途，含有它们的药物组合物，利用这种化合物制备用于治疗神经病性疼痛的药物制剂的用途，以及用于治疗这种疾病的方法在动物中，尤其是在人类中。
• 1,3-Dihydro-1-[(1-piperidinyl)alkyl]-2H-benzimidazol-2-one derivatives
  申请人：Janssen Pharmaceutica, N.V.

  公开号：US04254127A1

  公开（公告）日：1981-03-03

  Novel 1,3-dihydro-1-[(1-piperidinyl)alkyl]-2H-benzimidazol-2-one derivatives which compounds are potent serotonin-antagonists and central nervous system depressants, having utility as antiemetic, neuroleptic and anti-congestive agents.

  新型1,3-二氢-1-[(1-哌啶基)烷基]-2H-苯并咪唑-2-酮衍生物，这些化合物是有效的5-羟色胺拮抗剂和中枢神经系统抑制剂，具有作为抗恶心、神经阻滞剂和抗充血剂的用途。